Guided Intraoperative Scintigraphic Tumour Targeting (GOSTT); implementing advanced hybrid molecular imaging and non-imaging probes for advanced cancer management | Agenda Bookshop Skip to content
Selected Colleen Hoover Books at €9.99c | In-store & Online
Selected Colleen Hoover Books at €9.99c | In-store & Online
A01=International Atomic Energy Agency
Author_International Atomic Energy Agency
Category1=Non-Fiction
Category=NL-MB
COP=Austria
Discount=15
Format=BC
Format_Paperback
HMM=240
IMPN=IAEA
ISBN13=9789201022141
Language_English
NWS=29
PA=To order
PD=20140630
POP=Vienna
Price_€50 to €100
PS=Active
PUB=IAEA
SN=IAEA human health series
Subject=Medicine: General Issues

Guided Intraoperative Scintigraphic Tumour Targeting (GOSTT); implementing advanced hybrid molecular imaging and non-imaging probes for advanced cancer management

Paperback | English

By (author): International Atomic Energy Agency

This publication provides an updated source for professionals involved in employing guided intraoperative scintigraphic tumour targeting (GOSTT). Its content contributes to supporting both the clinical decision making process and the implementation of minimally invasive surgical procedures. The publication provides an update on innovations in the use of radiopharmaceuticals for sentinel lymph node mapping and sentinel lymph node biopsy. In addition, it provides an update on advances in the implementation of hybrid imaging technologies for the surgical management of patients with cancer in conjunction with intraoperative regional lymph node mapping. The experience with the use of small field scintigraphic imaging devices in the operating theatre is also presented. See more
Current price €89.19
Original price €104.93
Save 15%

Will deliver when available.

Product Details
  • Format: Paperback
  • Publication Date: 30 Jun 2014
  • Publisher: IAEA
  • Publication City/Country: Vienna, Austria
  • Language: English
  • ISBN13: 9789201022141
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept